Skip to main
CNTX
CNTX logo

CNTX Stock Forecast & Price Target

CNTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Context Therapeutics Inc. is positioned favorably in the biopharmaceutical landscape due to its promising pipeline, specifically the CTIM-76 program targeting CLDN6 in hormone-dependent cancers. The company's modest enterprise value of $9 million, coupled with early, favorable clinical data from comparable companies, suggests a strategic entry point for investors ahead of pivotal Phase 1 results that could significantly enhance valuation. Additionally, compelling preclinical data indicate that CTIM-76 could outperform expectations in treating ovarian cancer, further bolstering the company's positive prospects.

Bears say

Context Therapeutics Inc faces significant uncertainty regarding the clinical efficacy and safety of its preclinical program, CTIM-76, due to the absence of clinical data, raising concerns about potential competitive shortcomings and increased toxicities. Additionally, the company's market opportunity for CTIM-76 may be overestimated, pointing to a potential mismatch between projected benefits and actual market demand. Overall, the unfavorable risk/reward dynamics associated with the therapeutic's safety and efficacy profile contribute to a negative outlook on the company's stock performance.

CNTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Context Therapeutics LLC (CNTX) Forecast

Analysts have given CNTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, CNTX has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Context Therapeutics LLC (CNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.